Home > Products > Novel inhibitors

GSK621 (GSK 621;GSK-621)

  Cat. No.:  DC29234   Featured
Chemical Structure
1346607-05-3
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
Get Quotation Now
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
GSK621 (GSK-621) is a potent, specific AMPK agonist (activator), induces cytotoxicity in AML (IC50=13-30 uM) but not in normal hematopoietic cells; GSK621 is more potent than A-769662 at inducing AMPK activation, as measured by the level of ACC phosphoryl
Chemicals PropertiesBiological activity COA & MSDSRelated productsDatasheet
Cas No.: 1346607-05-3
Chemical Name: 6-chloro-5-(2'-hydroxy-3'-methoxy-[1,1'-biphenyl]-4-yl)-3-(3-methoxyphenyl)-1,5-dihydro-2H-pyrrolo[3,2-d]pyrimidine-2,4(3H)-dione
SMILES: O=C1NC2=C(N(C3=CC=C(C4=CC=CC(OC)=C4O)C=C3)C(Cl)=C2)C(N1C5=CC=CC(OC)=C5)=O
Formula: C26H20ClN3O5
M.Wt: 489.91
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: GSK621 is a specific AMPK activator, with IC50 values of 13-30 μM for AML cells. GSK621 induces autophagy and apoptosis. GSK621 induces eiF2α phosphorylation-a hallmark of UPR activation[1].
In Vivo: GSK621 (30 mg/kg, ip twice daily) exhibits significant anti-tumor activity in MOLM-14 cells xenograft[1]. Animal Model: MOLM-14 cells xenografted into nude mice[1]. Dosage: 30 mg/kg. Administration: IP twice daily. Result: Reduced leukemia growth and significantly extended survival compared to vehicle-treated animals or those treated with 10 mg/kg twice daily.
In Vitro: GSK621 (30 μM) induces AMPKα T172, ACC (S79) and ULK1 (S555) phosphorylation[1]. GSK621 (30 μM) induces autophagy and apoptosis[1]. GSK621 treatment also induces PERK phosphorylation, a marker of ER stress, in AML cells[1]. Cell Proliferation Assay[1] Cell Line: MV4-11, OCI-AML3, OCI-AML2, HL-60, Kasumi, HEL, UT7, NB4, TF-1, KG1A, Nomo p28, SKM-1, U937, YHP1, MOLM-14, Mo7e, K562, MOLM-13, EOL-1, SET-2 AML cell lines.0-30 μM. Concentration: 0-30 μM. Incubation Time: 4 d. Result: IC50 values ranged from 13 to 30 μM. Reduced the proliferation of all 20 lines and increased apoptosis in 17 (85%) lines. Cell Autophagy Assay[1]. Cell Line: AML cell lines and primary AML samples. Concentration: 30 μM. Incubation Time: 24 h. Result: Induced the formation of numerous intracytoplasmic vacuoles including autophagosomes.
References: [1]. Pierre Sujobert, et al. Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia. Cell Rep. 2015 Jun 9;11(9):1446-57.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
Cat. No. Product name Field of application
DC74251 BI-9774 BI-9774 (BI 9774) is a potent pan-AMPK activator with EC50 of 64 nM in an ADP-Glo kinase assay with human AMPK (α1β1γ1) and EC50 of 8 nM in a cellular GLUT4 translocation assay.
DC72738 YLF-466D YLF-466D is an AMPK activator that inhibits platelet aggregation with IC50 of 84 μM.
DC71255 MOTS-c MOTS-c, a mitochondria-derived peptide (MDP), exerts antinociceptive and anti-inflammatory effects through activating AMPK pathway and inhibiting MAP kinases-c-fos signaling pathway.
DC40041 RSVA405 RSVA405 is a potent, orally active activator of AMPK, with an EC50 of 1 μM. RSVA405 facilitates CaMKKβ-dependent activation of AMPK, inhibits mTOR, and promotes autophagy to increase Aβ degradation. RSVA405 has anti-inflammatory effects through the inhibition of STAT3 function. RSVA405 also can be used for the research of obesity.
DC39091 IM156 IM156, a metformin derivative, is a potent activator of AMPK that increases AMPK phosphorylation. IM156 blocks oxidative phosphorylation (OXPHOS) through the inhibition of complex I and increases apoptosis. IM156 ameliorates various types of fibrosis and
DC29234 GSK621 (GSK 621;GSK-621) GSK621 (GSK-621) is a potent, specific AMPK agonist (activator), induces cytotoxicity in AML (IC50=13-30 uM) but not in normal hematopoietic cells; GSK621 is more potent than A-769662 at inducing AMPK activation, as measured by the level of ACC phosphoryl
DC12020 MK-8722 MK-8722 is a systemic, Direct Pan-Activator of AMP-Activated Protein Kinase.
DC10978 BAY-3827 BAY-3827 (BAY3827) is a potent, selective inhibitor of AMPK as tool compound to evaluate the therapeutic potential of AMPK inhibition in MYC-dependent tumors; strongly inhibits Acetyl-CoA carboxylase (ACC) phosphorylation in COLO 320DM and IMR-32 cells, but fails to inhibit the proliferation of cells with dysregulated c-MYC or N-MYC.
DC11129 AMPK activator SC4 AMPK activator SC4 is a highly specific and potent activator of the α2β2-AMPK complexes, which are the predominant AMPK isoform complexes found in human skeletal muscle. SC4 demonstrates significant efficacy with EC50 values of 17.2 nM for the α2β2γ1 complex and 82.1 nM for the α2β2γ3 complex. These low EC50 values indicate that SC4 is effective at relatively low concentrations, making it a promising compound for targeting AMPK in skeletal muscle. This specificity and potency suggest potential therapeutic applications in conditions where AMPK activation is beneficial, such as metabolic disorders, muscle function, and energy homeostasis.
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia